Table 4.

Therapeutic end points for small molecule therapy of myeloproliferative disorders (MPD).

  • Survival

  • Clinical events

  • Hematologic parameters

  • JAK2 mutational status

  • Restoration of polyclonal hematopoiesis

  • Bone marrow histology and cytogenetics

  • Other biomarkers

 

  • Survival

  • Clinical events

  • Hematologic parameters

  • JAK2 mutational status

  • Restoration of polyclonal hematopoiesis

  • Bone marrow histology and cytogenetics

  • Other biomarkers

 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal